Clinical Trial

Transdiagnostic Dimensional Profiling of Neurodevelopmental Disorders

Study acronym: RDoC-CRAB
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
In recent years, the growing awareness of the multifactorial nature of neurodevelopmental disorders has stimulated interest in transdiagnostic approaches aimed at investigating underlying etiological mechanisms beyond traditional diagnostic categories. In this context, the present study seeks to provide a transdiagnostic profiling of both domain-general cognitive functions (attention, working memory, executive control) and domain-specific functions (phonological awareness, rapid naming, vocabulary, reading) underlying the main neurodevelopmental disorders in a large sample of preschool and school-age children (3-11 years), through the use of CRAB (Computerized Reading-related Assessment Battery). CRAB is a digital platform specifically developed by SUPSI and the Université de Genève to integrate, within a single testing environment, the assessment of the main domain-general and domain-specific cognitive functions underlying neurodevelopmental disorders. In particular, participating families will receive an email containing a link to access the CRAB platform, which will not include their personal data but rather a code provided by the staff of IRCCS Medea. A screen will open displaying several game-like tasks designed to measure both domain-general and domain-specific cognitive functions, which must be completed by the participating subject. The main objective is to obtain a fine-grained and multidimensional mapping of cognitive profiles prior to the standard diagnostic process, in order to identify early patterns of (a)typical or at-risk functioning.
Trial Details
NCT Number NCT07544199
Lead Sponsor IRCCS Eugenio Medea
Collaborators: Scuola Universitaria Professionale della Svizzera Italiana (SUPSI), University of Geneva, Switzerland
Conditions Neurodevelopmental Disorder (Diagnosis)
Enrollment 300 participants
Start Date 2026-05-01
Primary Completion 2029-04-30 (estimated)
Study Completion 2030-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-22